



ABN 53 075 582 740

## ASX ANNOUNCEMENT

30 April 2019

---

### Quarterly Cashflow Report

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report. During the quarter:

- As previously announced to the market on 18 February 2019, additional data analysis of the Phase 2 PTSD Trial (referred to as the RESTORE trial) conducted in Sweden by Pharmetheus AB showed a statistically significant response of BNC210 in the treatment of PTSD symptoms, as measured by CAPS-5 at 12 weeks when drug exposure versus response was measured. With these data Bionomics has been preparing for a Type C meeting with the FDA on the next steps for BNC210 for the treatment of PTSD, including the design of a further trial and whether BNC210 is eligible for Fast Track designation. No decision has been made about future trials at this stage. We continue to evaluate partnership opportunities in parallel as part of the ongoing strategic review being conducted by Greenhill & Co.
- Bionomics attended the 2nd Neuroscience Innovation Forum on 6th January 2019 and Biotech Showcase™ 2019 from 8th January to 10th January 2019 in San Francisco, coinciding with the 37th Annual JP Morgan Healthcare Conference and associated life sciences investment and partnering meetings, with the objective of advancing partnering of both CNS and Oncology assets.
- Whilst efforts to divest our oncology assets continue, an experimental Phase II clinical trial of our cancer drug candidate BNC105, in combination with nivolumab, has commenced in patients with metastatic colorectal cancer, in an Australasian Gastro-Intestinal Trials Group (AGITG) sponsored trial supported by Bristol-Myers Squibb.
- Greenhill & Co continue their work with Bionomics to assess the strategic options for partnering and portfolio prioritisation whilst protecting our major assets and conserving cash.
- Dr Errol De Souza's appointment as Executive Chairman of Bionomics was extended to 30 June 2019.

#### **The Company is progressing its BNC210 clinical trial for treatment of Agitation in Elderly Patients and advances other pre-clinical assets in its research pipeline.**

- Cash balance at 31 March 2019 was \$22.1m (31 December 2018: \$27.35m) with net operating cash outflow during the quarter ended 31 March 2019 of \$3.32m.
- Cash receipts for the quarter ending 31 March 2019 included receipts from customers totalling \$1.94m (31 December 2018: \$2.66m).
- Research & development costs reduced by 62% compared with the previous quarter following completion of the BNC210 Phase 2 Clinical Trial in PTSD.

Whilst section 9 of the Appendix 4C shows the estimated cash outflows for the next quarter ending 30 June 2019, no estimated cash inflows are provided. The estimated cash outflows are reliant on the timing of various activities, including clinical trials, being conducted by Bionomics.

### **Upcoming Milestones:**

- An announcement on the outcome of the Strategic Review led by Greenhill & Co is expected in the second quarter of CY2019.
- The BNC210 Phase 2 Agitation in the Elderly clinical trial results are expected in the second quarter of CY2019.
- Bionomics continues a limited research investment to progress an additional early stage ion channel program targeting cognition to therapeutic candidate identification and partnering of a potential therapeutic candidate for the treatment of pain.
- Whilst the internal focus and current R&D spend is restricted to CNS programs, Bionomics continues limited activities to maximize the value of its legacy oncology programs through divestment and/or out-licensing both BNC101 and BNC105.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

#### **Bionomics Ltd.**

Jack Moschakis  
Legal Counsel & Company Secretary  
+61 8 8354 6100  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

#### **About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

[www.bionomics.com.au](http://www.bionomics.com.au)

#### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

#### Name of entity

Bionomics Limited

#### ABN

53 075 582 740

#### Quarter ended ("current quarter")

31 March 2019

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
<b>1</b>	<b>Cash flows from operating activities</b>		
1.1	Receipts from customers	1,945	6,805
1.2	Payments for		
	(a) research and development	(3,852)	(18,361)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	(6)	(53)
	(e) staff costs	(772)	(1,871)
	(f) administration and corporate costs	(631)	(2,280)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	46	215
1.5	Interest and other costs of finance paid	(456)	(1,627)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	402	7,438
1.8	Other (provide details if material)	-	-
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(3,325)</b>	<b>(9,734)</b>
<b>2</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

**Appendix 4C**  
**Quarterly report for entities subject to Listing Rule 4.7B**

<b>Consolidated statement of cash flows</b>	<b>Current quarter</b>	<b>Year to date (9 months)</b>
	<b>\$A'000</b>	<b>\$A'000</b>
<b>3 Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	10,100
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	(1,912)	(3,169)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>(1,912)</b>	<b>6,931</b>

<b>4 Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	27,355	24,930
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(3,325)	(9,734)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(1,912)	6,931
4.5 Effect of movement in exchange rates on cash held	-	(10)
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>22,118</b>	<b>22,118</b>

<b>5 Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter</b>	<b>Previous quarter</b>
	<b>\$A'000</b>	<b>\$A'000</b>
5.1 Bank balances	22,118	27,351
5.2 Call deposits	-	-
5.3 Bank overdrafts		
5.4 Other (provide details)		
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>22,118</b>	<b>27,351</b>

**6 Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter</b>
<b>\$A'000</b>
178
-

*Remuneration paid to Chief Executive Officer/Managing Director and Non-Executive Directors*

**7 Payments to related entities of the entity and their associates**

**Current quarter**  
**\$A'000**

7.1 Aggregate amount of payments to these parties included in item 1.2

7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

--

**8 Financing facilities available**

*Add notes as necessary for an understanding of the position*

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

**Total facility amount at  
quarter end**

**Amount drawn at  
quarter end**

**\$A'000**

**\$A'000**

18,095

18,095

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

*Silicon Valley Bank US\$15m, interest 8.15%, secured by substantially all of the Group's assets, other than intellectual property.*

**9 Estimated cash outflows for next quarter**

**\$A'000**

9.1 Research and development

(1,572)

9.2 Product manufacturing and operating costs

-

9.3 Advertising and marketing

-

9.4 Leased assets

(4)

9.5 Staff costs

(484)

9.6 Administration and corporate costs

(822)

9.7 Other (provide details if material)

-

**9.8 Total estimated cash outflows**

**(2,882)**

**10 Acquisitions and disposals of business  
(items 2.1(b) and 2.2(b) above)**

**Acquisitions**

**Disposals**

10.1 Name of entity

10.2 Place of incorporation or registration

10.3 Consideration for acquisition or disposal

10.4 Total net assets

10.5 Nature of business

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: .....  
(Company Secretary)

Date: 30/04/2019 .....

Print name: Jack Moschakis .....

**Notes**

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.